Cargando…

Whose mu fared better? The effect of extended-release naltrexone (XR-NTX) on treatment outcomes for opioid and alcohol users

Detalles Bibliográficos
Autor principal:	Crèvecoeur-MacPhail, Desirée A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4347612/ http://dx.doi.org/10.1186/1940-0640-10-S1-A9

Ejemplares similares

Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
por: Nunes, Edward V., et al.
Publicado: (2015)

Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
por: Earley, Paul H., et al.
Publicado: (2017)

The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature
por: Ramsey, Susan E., et al.
Publicado: (2016)

Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD
por: Staton, Michele, et al.
Publicado: (2021)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Anhedonia to music and mu-opioids: Evidence from the administration of naltrexone
por: Mallik, Adiel, et al.
Publicado: (2017)

Naltrexone extended-release injection: an option for the management of opioid abuse
por: Taylor, Robert, et al.
Publicado: (2011)

Ethanol/Naltrexone Interactions at the mu-Opioid Receptor. CLSM/FCS Study in Live Cells
por: Vukojević, Vladana, et al.
Publicado: (2008)

Naltrexone is neuroprotective against traumatic brain injury in mu opioid receptor knockout mice
por: Wang, Yu‐Syuan, et al.
Publicado: (2021)

The Vivitrol pilot program (VPP): initial quantitative findings from an extended-release naltrexone study
por: Rieckmann, Traci, et al.
Publicado: (2015)

Consultants or Trainees: Whose patient's do better following surgical coronary revascularisation?
por: Balmforth, Damian, et al.
Publicado: (2015)

Naltrexone Implant for Opioid Use Disorder
por: Edinoff, Amber N., et al.
Publicado: (2021)

Comparison of physicochemical properties and biological activities of opioid morphinans interacting with mu opioid receptors
por: Asim, Muhammad F, et al.
Publicado: (2008)

Whose genome is next?
por: Kemmer, Danielle, et al.
Publicado: (2002)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Factors associated with willingness to take extended release naltrexone among injection drug users
por: Ahamad, Keith, et al.
Publicado: (2015)

Covid-19: did higher trust societies fare better?
por: Casey, Bernard H
Publicado: (2023)

Medication Treatment for Opioid Use Disorders:: A Brief Overview with Comments on Extended Release Naltrexone
por: Woody, George
Publicado: (2017)

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone
por: Marciuch, Anne, et al.
Publicado: (2023)

Venlafaxine extended release (XR) in the treatment of panic disorder
por: Kjernisted, Kevin, et al.
Publicado: (2007)

The opioid crisis fuelled by health systems: how will future physicians fare?
por: Kaggwa, Mark Mohan, et al.
Publicado: (2023)

Che fare?
por: Tolstoi, León, 1828-1910

No Reduction in Fare
Publicado: (1886)

Bill of Fare
Publicado: (1883)

Pathophysiology of COVID-19: Why Children Fare Better than Adults?
por: Dhochak, Nitin, et al.
Publicado: (2020)

Battle of the bees: will native or invasive bees fare better with climate change?
por: Guo, Lian
Publicado: (2021)

The relationship between reincarceration and treatment of opioid use disorder with extended-release naltrexone among persons with HIV
por: Parchinski, Kaley, et al.
Publicado: (2023)

Characteristics of Opioid-Users Whose Death Was Related to Opioid-Toxicity: A Population-Based Study in Ontario, Canada
por: Madadi, Parvaz, et al.
Publicado: (2013)

Epidemiologic and Molecular Pathophysiology of Chronic Opioid Dependence and the Place of Naltrexone Extended-Release Formulations in its Clinical Management
por: Reece, Albert Stuart
Publicado: (2012)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone
por: Karlsson, Ann Tarja, et al.
Publicado: (2022)

Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence
por: Li, Xinyi, et al.
Publicado: (2023)

An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence
por: Lin, Yufei, et al.
Publicado: (2020)

Screening for type 2 diabetes: do screen-detected cases fare better?
por: Feldman, Adina L., et al.
Publicado: (2017)

Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults?
por: Neaga, Alexandra, et al.
Publicado: (2021)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Reimbursement of Bus Fares
Publicado: (1954)

Christmas Fare for the Children
Publicado: (1892)

Bill of Fare for Diabetics
Publicado: (1879)

User satisfaction with train fares: A comparative analysis in five Australian cities
por: Paramita, Puteri, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_90b1sjvtu5niiqt115i6belri5